Group 1 innate lymphocyte-derived IFN- γ regulates macrophage alternative activation in colon cancer

Yandong Zhang

The First Hospital of Jilin University

Shu Ma

The First Hospital of Jilin University

Tie Li

The First Hospital of Jilin University

Yu Tian

The Affiliated Hospital of Yangzhou University, Yangzhou University

Huangao Zhou

The Affiliated Hospital of Yangzhou University, Yangzhou University

Hongsheng Wang

The Affiliated Hospital of Yangzhou University, Yangzhou University

Lan Huang (✉ lanhuangszsl@163.com)

Saint Louis University School of Medicine

Research Article

Keywords: Tumor-associated macrophage, M1 macrophage, Group 1 innate lymphocytes, Colon cancer, IFN- γ

Posted Date: September 28th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1160875/v2>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background

Tumor-associated macrophage (TAM) is an important innate immune cell-subset in tumor microenvironment, and that is also a pivotal orchestrator of tumor-promoting inflammation and tumor progression. Evidence proved that TAMs are up-regulated in a great number of cancers, and most of them are alternative activated M2 phenotype, which greatly promote the progress of cancer diseases. Group 1 innate lymphocytes including conventional NK cells and type 1 innate lymphocytes (ILC1s), are abundant in intestinal tissue, and characterized by expressing transcription factor T-bet and secreting interferon (IFN)- γ , which can promote the macrophage to classically activated anti-tumor M1 phenotype. However, the relationship between these two cell subsets remains unclear in colon cancer.

Methods

Flow cytometry was used to detect the percentage of M1 phenotype macrophage, M2 phenotype macrophage and group 1 innate lymphocytes in colon cancer tissue and paracancer healthy colon tissue of AOM/DSS-induced colon cancer mice model. *In vitro* isolating group 1 innate lymphocytes and inducing bone marrow-derived macrophage to detect the cross-talk when co-cultured. Adoptively transfer or blocking group 1 innate lymphocytes *in vivo* to explore the role of group 1 innate lymphocytes on tumor-infiltrating macrophage and the tumor growth.

Results

We found that M1 phenotype macrophage and group 1 innate lymphocytes were down-regulated in colon cancer tissue, and they were positively correlated. Group 1 innate lymphocytes promoted macrophage to classically activated M1 phenotype *in vitro*, and that could be blocked by anti-IFN- γ . *In vivo* results showed that the administration of group 1 innate lymphocytes-blocking antibody anti-NK1.1 could decrease the number of M1 phenotype macrophages in tumor tissue of MC38 tumor-bearing mice and promote the tumor growth, while adoptively transferring group 1 innate lymphocytes led to tumor-inhibiting and level of M1 phenotype macrophage up-regulating in MC38 tumor-bearing mice.

Conclusions

Our studies preliminarily prove that group 1 innate lymphocytes promote the alternative activation of M1 macrophage by secreting IFN- γ and inhibit the progress of colon cancer for the first time, which may provide an insight in the immunotherapy of colon cancer.

Introduction

Colon cancer is a malignant and lethal gastrointestinal cancer disease, which is the second leading reason of tumor-related death in the world[1]. Currently, surgery combined with radiotherapy and chemotherapy is the most common treatment to colon cancer though the therapeutic effect is not

satisfactory[2]. To date, immunotherapy, as a promising therapeutic strategy, has been applied in a variety of tumor diseases[3, 4]. Understanding the immune regulatory mechanism in the occurrence and development of colon cancer is a key step in developing immunotherapy strategies to treat colon cancer.

Innate lymphocytes (ILCs), as a subset of innate immune cells, participate in the regulation of multiple tumor diseases[5]. Studies have shown that ILCs are abundant in colon cancer tissue and play an important role in the development of colon cancer[6], but the regulatory mechanism is not fully clear. According to the transcription factors and secreted cytokines, ILCs are divided into three subsets, group 1 innate lymphocytes, group 2 innate lymphocytes, and group 3 innate lymphocytes[7]. Among of them, group 1 innate lymphocytes, which consist of conventional NK cells and ILC1s, are characterized by secreting interferon (IFN)- γ and tumor necrosis factor (TNF)- α , exerting a powerful anti-tumor function in various tumors[8]. TNF- α was proved to have a potent anti-tumor effect. It can not only kill tumors directly, but also recruit and stimulate anti-tumor macrophages and dendritic cells (DCs) to promote the anti-tumor effect. Besides, it is also required for the induction and activation of cytotoxic T cells (CTL), which is the most effective tumor-killing cells[9, 10]. IFN- γ , as a main effector factor of group 1 innate lymphocytes, is proved to inhibit the proliferation and angiogenesis of tumor cells and enhance the cytotoxic activity of CTL to promote the anti-tumor effect[11, 12]. It is worth noting that IFN- γ induces the classically activated M1 phenotype macrophage and then promotes the tumor-inhibiting effect[13, 14]. But it remains unclear if group1 innate lymphocytes could promote the M1 phenotype macrophage polarization in colon cancer.

Tumor-associated macrophages (TAMs) are the main myeloid cell-subset infiltrated in solid tumors, which play a key role in coordinating tumor-promoted inflammation[15]. It is reported that TAMs are mainly tumor-promoting M2 phenotype macrophage in tumor microenvironment, and under certain stimuli, TAM also could polarize into anti-tumor M1 phenotype macrophage. It has been proved this functional heterogeneity of TAMs is common in a variety of tumors[16, 17]. IFN- γ and Lipopolysaccharide (LPS) promote macrophage polarizing to classically activated anti-tumor M1 phenotype, while IL-4 and IL-13 result in the activation of M2 phenotype macrophage, and that could be used as the immunotherapy target in the macrophage-based tumor immunotherapy[18–20]. Studies have shown that M2 macrophages characterized by CD206 and Arg-1 expressing up-regulated in colon cancer microenvironment while M1 macrophage featured by CD86 and iNOS expressing decreased in colon cancer microenvironment, which leads to the immunosuppressive and tumor-promoting effect in colon cancer[21, 22]. Regulating the M1/M2 axis is a key approach in the immunotherapy of colon cancer[23]. However, the mechanism of M1 down-regulation in the colon cancer microenvironment is still not fully understood.

In this study, we found that M1 phenotype macrophage and group 1 innate lymphocytes were both down-regulated in colon cancer microenvironment, and the percentage of M1 phenotype macrophage is positively correlated with the percentage of group 1 innate lymphocytes. Furthermore, *in vitro* studies showed that group 1 innate lymphocytes promoted macrophage polarizing to M1 phenotype macrophage when co-cultured and this effect was reversed by anti-IFN- γ . *In vivo* results demonstrated that adoptively

transferred group 1 innate lymphocytes to MC38 tumor-bearing mice increased the percentage of M1 phenotype macrophage in tumor microenvironment and inhibited the tumor growth while administration of ILC1s-blocking antibody exhibited an opposite effect.

Materials And Methods

2.1 Mice

Male and Female C57BL/6 (8 weeks, 20 g) were purchased from the Animal Center of Jilin University (Jilin, China). All the mice were bred and maintained in a specific pathogen-free animal facility with a temperature of $23^{\circ}\text{C} \pm 2^{\circ}\text{C}$ and relative humidity of $55\% \pm 10\%$. All the animal experimental protocols were in accordance with the Guide for Care and Use of Laboratory Animals and approved by the Ethics Committee of the First Hospital of Jilin University (20200698).

2.2 Cell line and cell culture

Mice colon cancer cell line, MC38 and macrophage cell line, RAW264.7 were purchased from the Shanghai Cell Bank of Chinese Academy of Sciences (Shanghai, China). Mice bone marrow-derived macrophage (BMDM) was induction from C57BL/6 mice bone marrow, and mice group 1 innate lymphocytes were isolated from the spleen of C57BL/6 mice. Cells were cultured in the DMEM or RPMI1640 medium supplemented with 10% FBS. All the cells were cultured in a humidified incubator with 5% CO_2 and a 37°C temperature.

2.3 Isolation of group 1 innate lymphocytes

Group 1 innate lymphocytes were isolated from the spleen of C57BL/6 mice, with a method of combining magnetic beads and flow sorting. Collagenase II and DNase I were used to digesting the tumor tissue for 1 hour, and then go through the 70mesh screen to get the single cell suspension. Per-coll (BD, New Jersey, USA) was used to get the immune cells from digested tumor tissue single cell suspension[24]. Obtained cells were incubated with biotin-binding (anti-CD3 ϵ , anti-CD45R, anti-Gr-1, anti-CD11c, anti-CD11b, anti-Ter119, anti-TCR- $\alpha\beta$, and anti-FC ϵ RI) (Miltenyi, Belgish, Germany) to enrich Lineage-negative cells following the Miltenyi magnetic beads cell isolation protocol. Enriched lineage-negative single cell suspension stained with anti-mouse Lineage cocktail (Biolegend, 145-2C11, RB6-8C5, RA3-6B2, Ter-119, M1/70), anti-mouse CD127 (Biolegend, A7R34), anti-mouse NK1.1 (Biolegend, PK136), and anti-mouse NKp46 (Biolegend, 29A1.4) for flow cytometry sorting(BD FACS Melody)the Lineage⁻ CD127⁺ NK1.1⁺ NKp46⁺ cells, as group 1 innate lymphocytes and cultured in RPMI1640 medium containing 10% FBS and 0.5ng/ml IL-7 (Gibco, PMC0071).

2.4 Induction of bone marrow-derived macrophage

Obtaining the leg of C57BL/6 mice (8 weeks, female) and using a syringe to get bone marrow cells to 10 cm cell-culture plate in the clean bench. Washing the bone marrow cells for three time and making cells through the 70 μm cell strainer to a 15 ml cell collecting tube. 1000 rpm centrifuge for 5 minutes, adding

5 ml ACK to break red cells, and then 1000 rpm centrifuge for 5 minutes again. Culturing the bone marrow cells in 6-well plate with 4 ml culture medium (10% FBS and 20ng/ml M-CSF) and a 1×10^6 cell density. On the third day, changing half of the culture medium and adding the corresponding stimulate factor M-CSF. On the fifth day, changing all the culture medium and adding the corresponding stimulate factor M-CSF. On the seventh day, obtaining the bone marrow-derived macrophage (BMDM) for research, and the purity of BMDM is detected by flow cytometry (**Figure S1B**).

For co-culture of ILC1 and macrophages, we used RPMI 1640 medium containing 10% FBS and 0.5ng/ml IL-7. RAW264.7 or BMDM and ILC1 were mixed and co-cultured in 24 well-plate for 24 hours.

2.5 Building mice tumor model

For AOM/DSS-induced colitis-associated colon cancer, 8 weeks mice were intraperitoneal injected of azoxymethane (AOM, 10 mg/kg body weight) (Ray Biotech, Georgia, USA). 4 days later, the mice were treated with 1.5% dextran sodium sulfate (DSS) in drinking water for six days. Replacing the DSS water with common water for two weeks, then treated with 1.5% DSS water for another 6 days. After 3 cycle of DSS treated, evaluating the tumor formation. For MC38 tumor bearing mice model, collecting the cultured MC38 cells, and then the mice were subcutaneously injected in the right flank with 1×10^6 tumor cells. Tumor length (L), diameter and width (W) were measured with a caliper.

2.6 Flow cytometry analysis

Tumor tissues from MC38 tumor-bearing mice and colon cancer mice samples were isolated and cut into small pieces. Paracancer tissue as a control and digested as the tumor tissue. The tumor tissue pieces and paracancer tissue pieces were digested with digestion solution containing 5% FBS, collagenase II (1 mg/mL), DNase I (200 μ g/mL) and hyaluronidase (4U/mL) (Sigma, St. Louis, USA) in 37°C water bath for 30 minutes. 70 mesh-screen to collect digested single cells, centrifuge, and then obtain the single tumor tissue cell suspension. Anti-mouse CD45 (30-F11), anti-mouse F4/80 (BM8) were used to analyze macrophage, anti-mouse CD86 (A17199A) for M1 phenotype macrophage, anti-mouse CD206 (15 – 2) for M2 phenotype macrophage. anti-mouse Lineage (145-2C11), anti-mouse CD127 (A7R34), and anti-mouse T-bet (4B10) were used to detect group 1 innate lymphocytes. For surface staining, antibody mixed with single cell suspension (100 μ l/ 10^6 cells) for 20 minutes at 4 degree. For intracellular staining, cells were cultured in complete 1640 medium with phorbol 12-myristate (PMA, 1 μ g/ml), ionomycin (1 μ g/ml) and brefeldin A (10 μ g/ml) (eBioscience, San Diego, USA) for 4–6 hours. Collecting the cells, and then surface-stained, fixed, permeabilized. Using the Fixation and Permeabilization Buffer Kit (Thermo Fisher Scientific, Massachusetts, USA) to stain the intracellular factors following the manufacturer's recommendations. Cell samples were detected by CytoFLEXS (Beckman coulter) and data was analyzed by Flowjo7.6.

2.7 RNA isolation and quantitative of Real-time PCR

Total RNA was extracted by TRIZOL reagent (Thermo Scientific, Massachusetts, USA) according the manufacturer's recommendations. cDNA was reverse transcribed by total RNA using the ReverTra Ace

qPCR RT kit (Toyobo, Osaka, Japan). Real-time PCR was performed in duplicate using Bio-Rad SYBR Green Super Mix (TAKARA, Tokyo, Japan) according to the manufacturer's instructions. The Primers were designed using Premier 5.0 software and synthesized by Shanghai Invitrogen. The mouse IFN- γ and β -actin primer sequences were as follows: IFN- γ , Forward (5'_3'), TGGCGGTGCTGAGCTACTGG; Reverse (5'_3'), TGTACCAGGAGTGTCAAGGCTCTC. β -actin, Forward (5'_3'), TGGAAATCCTGTGGCATCCATGAAA; Reverse (5'_3'), TAAAACGCAGCTCAGTAACAGTCCG.

2.8 Western Blot Analysis:

Cells were lysed with radio immunoprecipitation assay (RIPA) buffer containing a complete protease inhibiting tablet, and then centrifuge to get the total protein. The concentration of extracted protein was detected by CBA kit. The equal total protein was loaded into gel and separated by 10% SDS-PAGE, and the transferred onto polyvinylidene fluoride (PVDF) transfer membrane (Bio-Rad, CA, USA). 5% BSA was used to block the non-specific binding at a room temperature for 2 hours. Washing the membrane with PBS for 1 time and then the membranes were incubator with iNOS and Arg-1 primary antibody and β -actin (Abcam, Shanghai, China) for one night. Washing the membranes with TBS supplemented 5% Tween 20 (TBST) for 3 times, each time for 10 minutes. Then incubate the second antibody at a room temperature for 1 hours. Luminescent Image Analyzer (Image Quant LAS4000mini, GE Healthcare, China) was used to detect the gene expression and relevant blots were quantified by ImageJ.

2.9 Statistical analysis

The Error bars represent the mean $\pm$ SEM, which was analyzed by GraphPad Prism Version 7 software (GraphPad Software, CA, USA). Each in vitro experiment was performed in triplicate and each in vitro experiment uses 3–6 mice per treatment group. Statistical significance was determined by a t-test and one-way ANOVA and statistical significance was defined as a p-value < 0.05.

Results

3.1 Macrophage is up-regulated in colon cancer microenvironment and is mainly M2 phenotype

Tumor-infiltrating macrophage has always been considered as one of the important factor regulating tumor development and progression, especially the ratio of anti-tumor M1 phenotype macrophage and tumor-promoting M2 phenotype macrophage [25, 26]. To examine the role of macrophages in colon cancer, we made the AOM/DSS-induced colon cancer mice model, and detected the percentage of tumor-infiltrating macrophage (CD45⁺ F4/80⁺), M1 phenotype macrophage (CD45⁺ F4/80⁺ CD86⁺), and M2 phenotype macrophage (CD45⁺ F4/80⁺ CD206⁺) in mouse colon cancer tissue and paracancer healthy colon tissue. Fc-receptor-blocking antibody was used before staining the macrophage for flow cytometry analysis, and flow cytometry results showed that tumor-infiltrating macrophage was up-regulated in the mouse colon cancer tissue compared to the healthy tissue (**Fig. 1A, B**), which is consistent with previous studies that macrophages increased in colon cancer microenvironment when tumor occurs [27]. Flow

cytometry result also proved that M1 phenotype macrophages decreased while M2 phenotype macrophage was increased in colon cancer microenvironment (**Fig. 1C, D, E, F, S1A**), which demonstrated that macrophages were polarized to tumor-promoting M2 phenotype in colon cancer microenvironment, then accelerated the cancer progression. But the mechanism of M1 phenotype macrophages decreasing and M2 phenotype macrophages increasing in colon cancer is not fully understood.

3.2 Group 1 innate lymphocytes is decreased in colon cancer microenvironment and is positive correlation with M1 phenotype macrophage

Previously studies showed that ILCs are abundant in intestinal tissue, and ILC2s-derived IL-4 can promote tumorigenesis by polarizing macrophage towards a pro-tumorigenic M2 phenotype[28–30]. Furthermore, group 1 innate lymphocytes are characterized by secreting IFN- γ , which can polarize macrophage towards M1 phenotype[31, 32]. On basis of this, we guessed that whether the decreased M1 phenotype macrophage is due to the down-regulated IFN- γ levels in cancer microenvironment. We detected the percentage of group 1 innate lymphocytes (CD45⁺ Lineage⁻ CD127⁺ T-bet⁺) in AOM/DSS-induced mice colon cancer tissue and paracancer healthy colon tissue. Flow cytometry result showed decreased group 1 innate lymphocytes in mouse colon cancer tissue compared to healthy tissue (**Fig. 2A, B, S1C**). RT-PCR result also showed the decreased expression of IFN- γ in mouse colon cancer tissue compared to healthy tissue (**Fig. 2C**). Besides, the M1 phenotype macrophages percentage were positive correlation with the group 1 innate lymphocytes percentage in mouse colon cancer tissue, while M2 phenotype macrophages were negative correlation. (**Fig. 2D, E**). Whether the decrease of M1 phenotype macrophage attributes to the decrease of group 1 innate lymphocytes in mouse colon cancer tissue remains unclear.

3.3 Group 1 innate lymphocytes promote M1 phenotype macrophage polarizing in vitro

To prove whether group 1 innate lymphocytes could promote macrophage polarizing towards a M1 phenotype, we sorted group 1 innate lymphocytes from mouse spleen and co-cultured with macrophage cell line RAW264.7 or bone marrow-derived macrophage (BMDM). Our results showed that CD86 was significantly up-regulated on RAW264.7 and BMDM when co-cultured with group 1 innate lymphocytes while CD206 expression was decreased (**Fig. 3A, B**). To determine whether group 1 innate lymphocyte-derived IFN- γ promotes the M1 phenotype polarization, we chose to add the neutralizing antibody of group 1 innate lymphocytes secreting factors, IFN- γ and TNF- α into co-cultured system. Flow cytometry results showed that anti-IFN- γ decreased the expression of CD86 on RAW264.7 and BMDM while anti-TNF- α failed to alter the CD86 expression (**Fig. 3C, D**). Western blotting result of iNOS (M1 phenotype macrophage protein) and Arg-1 (M2 phenotype macrophage protein) also proved this result (**Fig. 3E, F**). Together, our results showed that group 1 innate lymphocytes could promote macrophage polarize towards a M1 phenotype by secreting IFN- γ *in vitro*.

3.4 Adoptively transferred group 1 innate lymphocyte significantly decrease the tumor growth of MC38 tumor-bearing mice

To determine whether group 1 innate lymphocytes could regulate the polarization of tumor-infiltrated macrophage to participate in the progression of colon cancer, we isolated group 1 innate lymphocytes from mouse spleen and adoptively transferred 2×10^5 group 1 innate lymphocytes to mice after implanting MC38 cells for 3 days. At the endpoint of this research, we found that the tumor size and weight of group 1 innate lymphocyte-transferred mice significantly decreased compared to control mice (**Fig. 4A, B, C**). To prove if the distinguish of tumor growth in control and group 1 innate lymphocyte-transferred MC38 tumor-bearing mice is attributed to the phenotype change of tumor-infiltrated macrophage, we then tested the percentage of M1 and M2 phenotype macrophage in the tumor tissues of different groups. Flow cytometry results showed that the percentage of M2 macrophage was significantly decreased after adoptively transferred group 1 innate lymphocytes, while M1 macrophage increased simultaneously (**Fig. 4D, E, F**). Due to the anti-tumor effect of M1 phenotype macrophage, these results preliminarily explained that the tumor-growth inhibit effect in group 1 innate lymphocyte-transferred mice. Western blotting result also proved this phenomenon (**Fig. 4G**). The above in vitro experiments proved that the group 1 innate lymphocytes could promote macrophage to polarizing towards an anti-tumor M1 phenotype by secreting IFN- γ . So we wondered that whether the phenotype change of macrophage is due to the up-regulated group 1 innate lymphocytes and its-derived cytokine IFN- γ . Flow cytometry was used to detect the percentage of group 1 innate lymphocytes and IFN- γ in tumor tissue. Results showed that the percentage of group 1 innate lymphocytes in tumor microenvironment was significantly increased in group 1 innate lymphocyte-transferred mice, and that preliminarily proved that adoptively transferred group 1 innate lymphocytes seems arrive in tumor microenvironment(**Fig. 4H, I, S1D**). Flow cytometry result also proved that the level of IFN- γ was up-regulated in tumor of group 1 innate lymphocyte-transferred mice (**Fig. 4J, K**). Together, we preliminary proved that the group 1 innate lymphocytes could promote macrophage polarize towards a M1 phenotype to exert anti-tumor effect through secreting IFN- γ in vivo.

3.5 Blocking group 1 innate lymphocyte promotes the tumor growth of MC38 tumor-bearing mice by down-regulating M1 phenotype macrophage

To further proved that group 1 innate lymphocytes could exert anti-tumor function by reverse macrophage to anti-tumorigenesis M1 phenotype. We operated the group 1 innate lymphocyte-blocking assay with previous reported group 1 innate lymphocyte-neutralizing antibody, anti-NK1.1 (PK136, Biolegend), in MC38 tumor-bearing mice[33]. Our results demonstrated that blocking group 1 innate lymphocyte significantly promoted the tumor growth of MC38 tumor-bearing mice compared to control mice (**Fig. 5A, B, C**),and that directly proved the anti-tumor role of group 1 innate lymphocyte in MC38 tumor-baring mice.

To prove whether this effect rely on tumor-infiltrated macrophage, we detected the percentage of M1 and M2 phenotype macrophage in tumors of different groups. Flow cytometry results showed that blocking group 1 innate lymphocytes increased the levels of tumorigenesis M2 phenotype macrophage, meanwhile decreased the levels of anti-tumorigenesis M1 phenotype macrophage (**Fig. 5D, E, F**). Western blotting result also proved this phenomenon (**Fig. 5G**). These results further proved that the anti-tumor

role of group 1 innate lymphocytes might partially rely on the phenotype change of tumor-associated macrophage. To determine reason of the macrophage phenotype change, we detected the percentage of group 1 innate lymphocytes and IFN- γ expression level in tumors of different groups. Flow cytometry result showed that the percentage of group 1 innate lymphocytes and the level of IFN- γ significantly decreased in the tumors of group 1 innate lymphocyte-blocking mice (**Fig. 5H, J, I, K**). Together, these part results further proved the anti-tumorigenesis role group 1 innate lymphocytes, and preliminary demonstrated that group 1 innate lymphocytes might promote the macrophage phenotype change through secreting IFN- γ to exert the anti-tumorigenesis effect *in vivo*.

Discussion

In this study, we explored the potential relationship between tumor-infiltrated group 1 innate lymphocytes and TAM. We found that the percentage of group 1 innate lymphocytes and anti-tumorigenesis M1 phenotype macrophages were decreased in colon cancer microenvironment, and the decreased rate is positively correlated. *In vitro* results proved that group 1 innate lymphocytes could promote macrophage to polarizing to classical activated M1 phenotype, and this effect was reversed by anti-IFN- γ . This preliminarily demonstrated the potential relationship of group 1 innate lymphocytes and tumor-infiltrated macrophage, and partially explained the positive correlation of down-regulated rate of group 1 innate lymphocytes and M1 phenotype macrophage. *In vivo* studies uncovered that group 1 innate lymphocytes indeed inhibited the tumor growth and up-regulate the level of M1 phenotype macrophage while group 1 innate lymphocyte-blocking antibody promoted the tumor growth of MC38 tumor-bearing mice and down-regulating the M1 phenotype macrophage level. These results further proved the endogenously regulated approach of group 1 innate lymphocytes to tumor-infiltrated macrophage, and enriched our knowledge to the anti-tumor role of group 1 innate lymphocytes. Altogether, our study preliminarily proved that group 1 innate lymphocytes could promote the polarization of anti-tumor M1 phenotype macrophage through secreting IFN- γ in colon cancer microenvironment, thus inhibiting the tumor growth. It is worth noting that anti-NK1.1 did not only deplete ILC1s, but also deplete the NK cells, so we can only draw the conclusion that group 1 innate lymphocytes mediate the effect. However, group 1 innate lymphocytes consist of conventional NK cells and ILC1s, and it seems that ILC1s mainly mediate the effect. Therefore, more research should be done to confirm the exact cell subset, which is responsible for the effect we found. In our next project we will solve this problem. Furthermore, in the group 1 innate lymphoid cells transfer assay, we do not have direct evidence to prove that the up-regulated group 1 innate lymphoid cells in tumor microenvironment is attributed to the adoptively transfer, so the use of CD45 congenic mice and/or label the adoptively transferred group 1 innate lymphoid cells is needed to further prove our results in future work.

ILCs, as a special lymphoid cell-subset, were widely studied in recent years, and that do not express specific antigen receptor, but participates in a variety of diseases, such as allergic diseases, autoimmune diseases and tumor diseases[34, 35]. Compared to CD4⁺ T cells, ILCs are divided into three subset: Group 1 innate lymphocytes expressing transcription factor T-bet, characterized by secreting IFN- γ and TNF- α [36,

37]; group 2 innate lymphocytes expressing transcription factor ROR α and GATA3, characterized by secreting type II cytokines IL-4, IL-5, IL-9 and IL-13[38, 39]; and group 3 innate lymphocyte expressing transcription factor ROR γ t, characterized by secreting IL-17 and IL-22[40]. Group 1 innate lymphocytes, like Th1 cells, were reported to have a significant role in the intestine inflammatory diseases[41, 42]. In recent years, a great number of studies focused on the regulatory function of group 1 innate lymphocyte in tumor diseases[43]. Numerous studies showed the tumor-inhibiting effect of group 1 innate lymphocyte by secreting tumor-killing factors IFN- γ and TNF- α [44, 45]. Herein, we found a new way that group 1 innate lymphocyte exerted their anti-tumorigenesis function in colon cancer. We found that group 1 innate lymphocyte promoted the macrophage alternative activation to an anti-tumor M1 phenotype through secreting IFN- γ and then inhibiting the tumor growth, which highlight a new anti-tumor role by group 1 innate lymphocyte. But our study also has some limitations that we only clearly proved that group 1 innate lymphocyte could promote the induction of M1 phenotype macrophage by secreting IFN- γ *in vitro*, and our *in vivo* results does not show the directly effect of group 1 innate lymphocyte on tumor-infiltrated macrophage by secreting IFN- γ to exert anti-tumor role in the tumor microenvironment. We only preliminary proved this phenomenon, more evidences should be explored to further clarify these findings.

Tumor microenvironment (TME) is an abstract space where tumor grows and invades, and that is composed of tumor cells, interstitial cells, immune cells, capillaries, intercellular substance, tissue fluid and biomolecules[46]. Mostly TME is a highly immunosuppressive environment, which is why the tumor evades the host's immune surveillance, and grows out of control[47, 48]. Studies have proved that the incompetent and exhausted effector T cells[49], myeloid-derived suppressor cells (MDSCs)[50], TAM[51], regulatory T cells[52] and a variety of immunosuppressive factors are the main actors to form the immunosuppressive microenvironment of TME[53]. Among them, TAM especially plays a critical role, due to that they are the main immune cells infiltrated in the tumor microenvironment[54]. They can recognize and eliminate tumor cells, but as tumors occurring and developing, they are polarized to M2 phenotype, and play a promotional role in tumor growth, invasion and metastasis[55]. TAM is a "double-edged sword" in the occurrence and development of tumors. Finding out the reason why TAM has dual roles, which are anti-tumor M1 phenotype and tumor-promoting M2 phenotype, is a key step in macrophage-based tumor immunotherapy. Studies proved that immunosuppressive TME always promote macrophage polarized to a M2 phenotype, which greatly further exacerbate tumor invasion and growth. Here we found that M2 phenotype macrophages were greatly up-regulated in colon tumor tissue compared to healthy tissue, and that promoted the tumor growth. Reversing the M1 and M2 phenotype by adoptively transferred ILC1s, greatly increased the levels of M1 phenotype and inhibited the tumor growth, which directly proved that the ratio of M1/M2 phenotype macrophage is important for the development of tumors. How to increase the M1 phenotype macrophage and decrease the M2 phenotype macrophage level is an important task for tumor immunotherapy.

Conclusion

Our studies found that decreased group 1 innate lymphocytes level might contribute to increased tumor-promoting M2 phenotype macrophages. Group 1 innate lymphocytes could promote the polarization of

macrophage to M1 phenotype through secreting IFN- γ . *In vivo* studies demonstrated that adoptively transferred group 1 innate lymphocytes increased the M1 phenotype macrophages and inhibited the tumor growth, while depletion of group 1 innate lymphocytes reached the opposite. Our study may provide an insight in the immunotherapy of colon cancer.

Abbreviations

TAM: Tumor-associated macrophage; ILC1s: Type 1 innate lymphocytes; IFN- γ : Interferon- γ ; ILCs: Innate lymphocytes; TNF- α : Tumor necrosis factor- α ; DCs: Dendritic cells; CTL: Cytotoxic T cells; BMDM: Bone marrow-derived macrophage; TME: Tumor microenvironment; MDSCs: Myeloid-derived suppressor cells

Declarations

Ethics approval and consent to participate

All the animal experimental protocols were in accordance with the Guide for Care and Use of Laboratory Animals and approved by the Ethics Committee of the First Hospital of Jilin University (20200698), followed the guide lines adapted from the “Animal Welfare Act” (the federal law governing the care and use of laboratory animals in the United States). All methods were reported in accordance with ARRIVE guidelines for the reporting of animal experiments.

Consent for publication

Not applicable

Availability of data and materials

The data used to support the findings of this study are available in the supplemental data.

Declaration of competing interest

The authors declare that they have no competing interests.

Authors' contributions

Yandong Zhang did the research and wrote the manuscript. Shu Ma, Tie Li and Yu Tian modified the language. Huangao Zhou and Hongsheng Wang revised the study. Lan Huang designed the study, drafted, and revised the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by the "Science and Education Revitalize Health" Youth Science and Technology Project of Suzhou (grant no. KJXW2021043).

Acknowledgment

We thank all the people who help with our work.

Supplementary description

We declare that all methods are reported in accordance with the Guide for Care and Use of Laboratory Animals.

References

1. Wen J, Min X, Shen M, Hua Q, Han Y, Zhao L, Liu L, Huang G, Liu J, Zhao X: ACLY facilitates colon cancer cell metastasis by CTNNB1. *Journal of experimental & clinical cancer research* : CR 2019, 38(1):401.
2. Otani K, Kawai K, Hata K, Tanaka T, Nishikawa T, Sasaki K, Kaneko M, Murono K, Emoto S, Nozawa H: Colon cancer with perforation. *Surgery today* 2019, 49(1):15-20.
3. Yang Y: Cancer immunotherapy: harnessing the immune system to battle cancer. *The Journal of clinical investigation* 2015, 125(9):3335-3337.
4. Kouidhi S, Ben Ayed F, Benammar Elgaaied A: Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy. *Frontiers in immunology* 2018, 9:353.
5. Wagner M, Koyasu S: Cancer Immunoediting by Innate Lymphoid Cells. *Trends in immunology* 2019, 40(5):415-430.
6. Wang S, Qu Y, Xia P, Chen Y, Zhu X, Zhang J, Wang G, Tian Y, Ying J, Fan Z: Transdifferentiation of tumor infiltrating innate lymphoid cells during progression of colorectal cancer. *Cell research* 2020, 30(7):610-622.
7. Blom B, van Hoeven V, Hazenberg MD: ILCs in hematologic malignancies: Tumor cell killers and tissue healers. *Seminars in immunology* 2019, 41:101279.
8. Chiossone L, Dumas PY, Vienne M, Vivier E: Natural killer cells and other innate lymphoid cells in cancer. *Nature reviews Immunology* 2018, 18(11):671-688.
9. Balkwill F: Tumour necrosis factor and cancer. *Nature reviews Cancer* 2009, 9(5):361-371.
10. Aggarwal BB, Gupta SC, Kim JH: Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. *Blood* 2012, 119(3):651-665.
11. Gao Y, Yang J, Cai Y, Fu S, Zhang N, Fu X, Li L: IFN- γ -mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling. *International journal of cancer* 2018, 143(4):931-943.
12. Hirata A, Hashimoto H, Shibasaki C, Narumi K, Aoki K: Intratumoral IFN- α gene delivery reduces tumor-infiltrating regulatory T cells through the downregulation of tumor CCL17 expression. *Cancer gene therapy* 2019, 26(9-10):334-343.

13. Orecchioni M, Ghosheh Y, Pramod AB, Ley K: Macrophage Polarization: Different Gene Signatures in M1(LPS+) vs. Classically and M2(LPS-) vs. Alternatively Activated Macrophages. *Frontiers in immunology* 2019, 10:1084.
14. Mezouar S, Mege JL: Changing the paradigm of IFN- γ at the interface between innate and adaptive immunity: Macrophage-derived IFN- γ . *Journal of leukocyte biology* 2020, 108(1):419-426.
15. Yin M, Shen J, Yu S, Fei J, Zhu X, Zhao J, Zhai L, Sadhukhan A, Zhou J: Tumor-Associated Macrophages (TAMs): A Critical Activator In Ovarian Cancer Metastasis. *OncoTargets and therapy* 2019, 12:8687-8699.
16. Ge Z, Ding S: The Crosstalk Between Tumor-Associated Macrophages (TAMs) and Tumor Cells and the Corresponding Targeted Therapy. *Frontiers in oncology* 2020, 10:590941.
17. Pan Y, Yu Y, Wang X, Zhang T: Tumor-Associated Macrophages in Tumor Immunity. *Frontiers in immunology* 2020, 11:583084.
18. Pervin M, Karim MR, Kuramochi M, Izawa T, Kuwamura M, Yamate J: Macrophage Populations and Expression of Regulatory Inflammatory Factors in Hepatic Macrophage-depleted Rat Livers under Lipopolysaccharide (LPS) Treatment. *Toxicologic pathology* 2018, 46(5):540-552.
19. Zhang W, Zhang Y, He Y, Wang X, Fang Q: Lipopolysaccharide mediates time-dependent macrophage M1/M2 polarization through the Tim-3/Galectin-9 signalling pathway. *Experimental cell research* 2019, 376(2):124-132.
20. Gao S, Zhou J, Liu N, Wang L, Gao Q, Wu Y, Zhao Q, Liu P, Wang S, Liu Y et al: Curcumin induces M2 macrophage polarization by secretion IL-4 and/or IL-13. *Journal of molecular and cellular cardiology* 2015, 85:131-139.
21. Zhang L, Li Z, Skrzypczynska KM, Fang Q, Zhang W, O'Brien SA, He Y, Wang L, Zhang Q, Kim A et al: Single-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in Colon Cancer. *Cell* 2020, 181(2):442-459.e429.
22. Yahaya MAF, Lila MAM, Ismail S, Zainol M, Afizan N: Tumour-Associated Macrophages (TAMs) in Colon Cancer and How to Reeducate Them. *Journal of immunology research* 2019, 2019:2368249.
23. Zhang N, Liu C, Jin L, Zhang R, Wang T, Wang Q, Chen J, Yang F, Siebert HC, Zheng X: Ketogenic Diet Elicits Antitumor Properties through Inducing Oxidative Stress, Inhibiting MMP-9 Expression, and Rebalancing M1/M2 Tumor-Associated Macrophage Phenotype in a Mouse Model of Colon Cancer. *Journal of agricultural and food chemistry* 2020, 68(40):11182-11196.
24. Wang Y, Yin K, Tian J, Xia X, Ma J, Tang X, Xu H, Wang S: Granulocytic Myeloid-Derived Suppressor Cells Promote the Stemness of Colorectal Cancer Cells through Exosomal S100A9. *Advanced science (Weinheim, Baden-Wurtemberg, Germany)* 2019, 6(18):1901278.
25. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A: Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. *Trends in immunology* 2002, 23(11):549-555.
26. Goswami KK, Ghosh T, Ghosh S, Sarkar M, Bose A, Baral R: Tumor promoting role of anti-tumor macrophages in tumor microenvironment. *Cellular immunology* 2017, 316:1-10.

27. Fang M, Li Y, Huang K, Qi S, Zhang J, Zgodzinski W, Majewski M, Wallner G, Gozdz S, Macek P et al: IL33 Promotes Colon Cancer Cell Stemness via JNK Activation and Macrophage Recruitment. *Cancer research* 2017, 77(10):2735-2745.
28. Rao A, Strauss O, Kokkinou E, Bruchard M, Tripathi KP, Schlums H, Carrasco A, Mazzurana L, Konya V, Villablanca EJ et al: Cytokines regulate the antigen-presenting characteristics of human circulating and tissue-resident intestinal ILCs. *Nature communications* 2020, 11(1):2049.
29. Schneider C, Lee J, Koga S, Ricardo-Gonzalez RR, Nussbaum JC, Smith LK, Villeda SA, Liang HE, Locksley RM: Tissue-Resident Group 2 Innate Lymphoid Cells Differentiate by Layered Ontogeny and In Situ Perinatal Priming. *Immunity* 2019, 50(6):1425-1438.e1425.
30. Wan J, Cai W, Wang H, Cheng J, Su Z, Wang S, Xu H: Role of type 2 innate lymphoid cell and its related cytokines in tumor immunity. *Journal of cellular physiology* 2020, 235(4):3249-3257.
31. Nabekura T, Riggan L, Hildreth AD, O'Sullivan TE, Shibuya A: Type 1 Innate Lymphoid Cells Protect Mice from Acute Liver Injury via Interferon- γ Secretion for Upregulating Bcl-xL Expression in Hepatocytes. *Immunity* 2020, 52(1):96-108.e109.
32. Vogel DY, Glim JE, Stavenuiter AW, Breur M, Heijnen P, Amor S, Dijkstra CD, Beelen RH: Human macrophage polarization in vitro: maturation and activation methods compared. *Immunobiology* 2014, 219(9):695-703.
33. Wu C, He S, Liu J, Wang B, Lin J, Duan Y, Gao X, Li D: Type 1 innate lymphoid cell aggravation of atherosclerosis is mediated through TLR4. *Scandinavian journal of immunology* 2018, 87(5):e12661.
34. Yuan X, Rasul F, Nashan B, Sun C: Innate lymphoid cells and cancer: Role in tumor progression and inhibition. *European journal of immunology* 2021.
35. Poonpanichakul T, Chan-In W, Opasawatchai A, Loison F, Matangkasombut O, Charoensawan V, Matangkasombut P: Innate Lymphoid Cells Activation and Transcriptomic Changes in Response to Human Dengue Infection. *Frontiers in immunology* 2021, 12:599805.
36. Ducimetière L, Lucchiari G, Litscher G, Nater M, Heeb L, Nuñez NG, Wyss L, Burri D, Vermeer M, Gschwend J et al: Conventional NK cells and tissue-resident ILC1s join forces to control liver metastasis. *Proceedings of the National Academy of Sciences of the United States of America* 2021, 118(27).
37. Bai L, Vienne M, Tang L, Kerdiles Y, Etienne M, Escalière B, Galluso J, Wei H, Sun R, Vivier E et al: Liver type 1 innate lymphoid cells develop locally via an interferon- γ -dependent loop. *Science (New York, NY)* 2021, 371(6536).
38. Shen C, Liu C, Zhang Z, Ping Y, Shao J, Tian Y, Yu W, Qin G, Liu S, Wang L et al: PD-1 Affects the Immunosuppressive Function of Group 2 Innate Lymphoid Cells in Human Non-Small Cell Lung Cancer. *Frontiers in immunology* 2021, 12:680055.
39. Srinivasan A, Bajana S, Pankow A, Yuen C, Shah RK, Sun XH: Type 2 innate lymphoid cells from Id1 transgenic mice alleviate skin manifestations of graft-versus-host disease. *BMC immunology* 2021, 22(1):46.

40. Chang Y, Kim JW, Yang S, Chung DH, Ko JS, Moon JS, Kim HY: Increased GM-CSF-producing NCR(-) ILC3s and neutrophils in the intestinal mucosa exacerbate inflammatory bowel disease. *Clinical & translational immunology* 2021, 10(7):e1311.
41. Clark JT, Christian DA, Gullicksrud JA, Perry JA, Park J, Jacquet M, Tarrant JC, Radaelli E, Silver J, Hunter CA: IL-33 promotes innate lymphoid cell-dependent IFN- γ production required for innate immunity to *Toxoplasma gondii*. *eLife* 2021, 10.
42. Castleman MJ, Dillon SM, Purba C, Cogswell AC, McCarter M, Barker E, Wilson C: Enteric bacteria induce IFN γ and Granzyme B from human colonic Group 1 Innate Lymphoid Cells. *Gut microbes* 2020, 12(1):1667723.
43. Moreno-Nieves UY, Tay JK, Saumyaa S, Horowitz NB, Shin JH, Mohammad IA, Luca B, Mundy DC, Gulati GS, Bedi N et al: Landscape of innate lymphoid cells in human head and neck cancer reveals divergent NK cell states in the tumor microenvironment. *Proceedings of the National Academy of Sciences of the United States of America* 2021, 118(28).
44. Nabekura T, Shibuya A: Type 1 innate lymphoid cells: Soldiers at the front line of immunity. *Biomedical journal* 2021, 44(2):115-122.
45. Luci C, Bihl F, Bourdely P, Khou S, Popa A, Meghraoui-Kheddar A, Vermeulen O, Elaldi R, Poissonnet G, Sudaka A et al: Cutaneous Squamous Cell Carcinoma Development Is Associated with a Temporal Infiltration of ILC1 and NK Cells with Immune Dysfunctions. *The Journal of investigative dermatology* 2021.
46. Bianchi G, Czarnecki PG, Ho M, Roccaro AM, Sacco A, Kawano Y, Gullà A, Aktas Samur A, Chen T, Wen K et al: ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment. *Blood cancer discovery* 2021, 2(4):338-353.
47. Russell BL, Sooklal SA, Malindisa ST, Daka LJ, Ntwasa M: The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy. *Frontiers in oncology* 2021, 11:641428.
48. Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP et al: Efficacy, Safety and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. *Cancer discovery* 2021.
49. Gabriel SS, Tsui C, Chisanga D, Weber F, Llano-León M, Gubser PM, Bartholin L, Souza-Fonseca-Guimaraes F, Huntington ND, Shi W et al: Transforming growth factor- β -regulated mTOR activity preserves cellular metabolism to maintain long-term T cell responses in chronic infection. *Immunity* 2021.
50. Imazeki H, Ogiwara Y, Kawamura M, Boku N, Kudo-Saito C: CD11b(+)CTLA4(+) myeloid cells are a key driver of tumor evasion in colorectal cancer. *Journal for immunotherapy of cancer* 2021, 9(7).
51. Wang Y, Miao Z, Qin X, Li B, Han Y: NOD2 deficiency confers a pro-tumorigenic macrophage phenotype to promote lung adenocarcinoma progression. *Journal of cellular and molecular medicine* 2021.

52. Liu H, Yu Z, Tang B, Miao S, Qin C, Li Y, Liang Z, Shi Y, Zhang Y, Wang Q et al: LYG1 Deficiency Attenuates the Severity of Acute Graft-Versus-Host Disease via Skewing Allogeneic T Cells Polarization Towards Treg Cells. *Frontiers in immunology* 2021, 12:647894.
53. Trebska-McGowan K, Chaib M, Alvarez MA, Kansal R, Pingili AK, Shibata D, Makowski L, Glazer ES: TGF- β Alters the Proportion of Infiltrating Immune Cells in a Pancreatic Ductal Adenocarcinoma. *Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract* 2021.
54. Yu S, Li Q, Wang Y, Cui Y, Yu Y, Li W, Liu F, Liu T: Tumor-derived LIF promotes chemoresistance via activating tumor-associated macrophages in gastric cancers. *Experimental cell research* 2021:112734.
55. Wang X, Ji Y, Feng P, Liu R, Li G, Zheng J, Xue Y, Wei Y, Ji C, Chen D et al: The m6A Reader IGF2BP2 Regulates Macrophage Phenotypic Activation and Inflammatory Diseases by Stabilizing TSC1 and PPAR γ . *Advanced science (Weinheim, Baden-Wurtemberg, Germany)* 2021, 8(13):2100209.

Figures

Figure 1

M2 phenotype macrophage up-regulated in colon cancer tissue

A: representative flow cytometry graphs of getting the colon cancer tissue and paracancer control tissue macrophage from AOM/DSS-induced mice colon cancer model, Fc-receptor-blocking antibody was used before staining the macrophage for flow cytometry analysis. **B:** percentage of macrophage (CD45⁺F4/80⁺) in tumor tissue and control, n=5. **C and D:** percentage of M2 phenotype macrophage (CD45⁺F4/80⁺CD206⁺) was detected by flow cytometry, n=5. **E and F:** percentage of M1 phenotype macrophage (CD45⁺F4/80⁺CD86⁺) was detected by flow cytometry, n=5. All the experiments repeated for 3 times. Data are shown as mean $\pm$ SD (n = 5 per group, *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001).

Figure 2

Percentage of group 1 innate lymphocyte is positive correlation with the level of M1 phenotype macrophage

A: representative flow cytometry graphs of getting the colon cancer tissue and paracancer control tissue group 1 innate lymphocytes from AOM/DSS-induced mice colon cancer model. **B:** percentage of group 1 innate lymphocytes (CD45⁺Lineage⁻CD127⁺T-bet⁺) in tumor tissue and control, n=5. **C:** relative expression of IFN- γ in cancer tissue and control was detected by RT-PCR. **D and E:** the levels of tumor-infiltrated group 1 innate lymphocytes compared to tumor-infiltrated M1 and M2 phenotype macrophage was made the regression analysis. All the experiments repeated for 3 times. Data are shown as mean $\pm$ SD (n = 5 per group, *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001).

Figure 3

Group 1 innate lymphocytes promote M1 phenotype macrophage polarizing in vitro

Sorted group 1 innate lymphocytes(1×10^5) from mouse spleen co-cultured with macrophage cell line RAW264.7 (1×10^5) and bone marrow-derived macrophage (BMDM)for 24 hours.**A**:representative flow cytometry graphs of the expression of CD206 and CD86 in group 1 innate lymphocytes co-cultured RAW264.7 and control RAW264.7. **B**: representative flow cytometry graphs of the expression of CD206 and CD86 in group 1 innate lymphocytes co-cultured BMDM and control BMDM. **C and D**: 10 ug/ml anti-IFN- γ and TNF- α were added to co-culture system, flow cytometry was used to detected the expression of CD206 and CD86 in RAW264.7 and BMDM of different treated groups. **E**: western blotting was used to detect the expression of iNOS and Arg-1 in group 1 innate lymphocytes co-cultured, anti-IFN- γ and TNF- α treated co-culture system, and control RAW264.7. **F**: western blotting was used to detect the expression of iNOS and Arg-1 in group 1 innate lymphocytes co-cultured, anti-IFN- γ and TNF- α treated co-culture system, and control BMDM. All the experiments repeated for 3 times.

Figure 4

Adoptively transferred group 1 innate lymphocytes inhibit the tumor growth of MC38 tumor-bearing mice by promoting the M1 phenotype macrophage polarization

A-C: the tumor graph, tumor weight, and tumor volume in 2×10^5 group 1 innate lymphocytes adoptively transferred mice and control mice. **D:** representative flow cytometry graphs of getting the tumor tissue

macrophage. **E:** percentage of M1 phenotype macrophage (CD45⁺F4/80⁺CD86⁺) in the tumor of group 1 innate lymphocytes adoptively transferred mice and control mice was detected by flow cytometry. **F:** percentage of M2 phenotype macrophage (CD45⁺F4/80⁺CD206⁺) in the tumor of group 1 innate lymphocytes adoptively transferred mice and control mice was detected by flow cytometry. **G:** western blotting was used to detect the expression of iNOS and Arg-1 in the tumor of group 1 innate lymphocytes adoptively transferred mice and control mice. **H:** representative flow cytometry graphs of getting the tumor tissue group 1 innate lymphocytes in different groups. **I:** percentage of group 1 innate lymphocytes in different groups. **J:** representative flow cytometry graphs of getting the tumor tissue IFN- γ in different groups. **K:** the expression level of IFN- γ in the tumor of group 1 innate lymphocytes adoptively transferred mice and control mice. All the experiments repeated for 3 times, n=5. Data are shown as mean $\pm$ SD (n = 5 per group, *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001).

Figure 5

Blocking group 1 innate lymphocytes promoting the tumor growth of MC38 tumor-bearing mice by inhibiting the M1 phenotype macrophage polarization

A-C: the tumor graph, tumor weight, and tumor volume in group 1 innate lymphocyte-blocking mice and control mice, n=5. **D:** representative flow cytometry graphs of getting the tumor tissue macrophage. **E:**

percentage of M1 phenotype macrophage (CD45⁺F4/80⁺CD86⁺) in the tumor of ILC1s-blocking mice and control mice was detected by flow cytometry, n=5. **F:** percentage of M2 phenotype macrophage (CD45⁺F4/80⁺CD206⁺) in the tumor of group 1 innate lymphocyte-blocking mice and control mice was detected by flow cytometry, n=5. **G:** western blotting was used to detect the expression of iNOS and Arg-1 in the tumor of group 1 innate lymphocyte-blocking mice and control mice. **H:** representative flow cytometry graphs of getting the tumor tissue ILC1s in different groups. **I:** percentage of group 1 innate lymphocytes in different groups, n=5. **J:** representative flow cytometry graphs of getting the tumor tissue IFN- γ in different groups. **K:** the expression level of IFN- γ in the tumor of group 1 innate lymphocyte-blocking mice and control mice, n=5. All the experiments repeated for 3 times. Data are shown as mean $\pm$ SD (n = 5 per group, *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [figureS1.png](#)